2025-06-11-Jefferies-ALS（ALQ）_伟大的业务_但问题仍然存在_14页_614kb

ALQ Summary: Forecast Adjustments and Investment Analysis

Core Content

ALQ is a leading global testing and inspection company with two main segments: Life Sciences and Commodities. The firm's FY25 results and FY26 outlook were impacted by a significant capital expenditure (capex) program and an over-raise in equity, which raised concerns among investors. Despite these challenges, the company continues to operate in a competitive market, with a focus on growth and margin improvements.

Main Points

1. Forecast Adjustments

• The company's Life Sciences (LS) segment is the primary focus of earnings adjustments.
• EBIT for LS is trimmed by -1%, -4%, and -1% for FY26, FY27, and FY28 respectively.
• EPS is adjusted downward by -1%, -5%, and -2% for the same periods.
• Despite the forecast changes, the Price Target (PT) remains at A$18.20 due to a blended valuation model.

2. Segment Performance

• Life Sciences:
  • Expected to grow at 7% in FY26, with a focus on organic growth, margin expansion, and integration of recent acquisitions.
  • Legacy operations are expected to improve margins by 20-40bps in FY26.
  • Wessling and York, acquired in FY24, are expected to improve margins and contribute to EBIT.
  • Nuvisan remains a key uncertainty due to unclear revenue outlook and potential risks in the short term.
  • Regulatory changes in Mexico (pharma) could negatively impact EBIT by A$5m–A$10m in FY26.
• Commodities:
  • Expected to maintain stable revenue growth and margin improvements.
  • The segment is currently in an up-cycle, with a positive outlook for gold and copper prices.
  • EBITDA margins for the segment are expected to increase slightly.

3. Valuation and Investment Thesis

• The company is valued using a blend of DCF (50%) and EV/EBIT (50%), with a 10% premium ascribed to the Minerals segment due to the up-cycle.
• The blended valuation is A$18.60, leading to a PT of A$18.20.
• The base case assumes continued growth in LS and Commodities, with a PT of A$18.20.
• The upside scenario assumes higher-than-expected growth in geochemistry samples, leading to a PT of A$19.70.
• The downside scenario assumes negative trends in both segments, leading to a PT of A$15.30.

4. Key Questions and Concerns

• Why did ALQ over-raise equity when the lab expansion is not expected to benefit significantly until FY30?
• Why are four major labs simultaneously facing capacity constraints?
• Will new customer wins offset the decline in anchor revenue over the next two years?
• How long will it take for Wessling/York to reach the core Life Sciences EBIT margin of 17%?
• Is ALQ now back in M&A mode due to the over-raise?
• Why is the FY27 Group EBIT target so low-ball compared to the Minerals up-cycle?

5. Investment Catalysts

• Equity raisings data from junior miners.
• Half-yearly and full-year results.
• News flow around global exploration spend and geochemistry testing.
• Additional M&A activity.

Key Financial Highlights

EBIT Waterfall for Life Sciences (FY26E)

• Organic revenue growth: +A$20m
• Additional 2 months of Wessling: +A$4m–A$5m
• Wessling/York margin improvement: +A$4m
• Legacy margin uplift: +A$5m
• Mexico pharma regulations: -A$5m (Guided -A$5m to -A$10m)
• Nuvisan net improvement: +A$7m

Valuation Metrics

Investment Thesis

• ALQ is a major TIC company with a defensive segment (Life Sciences) and a cyclical segment (Commodities).
• The company has a strong market position in geochemistry testing (over 50% market share).
• The up-cycle in Minerals is expected to drive growth, but the capex program and equity raise are viewed as overkill.
• The company's sustainability goals include zero harm and a 40% reduction in carbon intensity by 2030.
• Key questions remain about the sustainability of growth, the impact of new regulations, and the effectiveness of cost-out initiatives.

Summary

ALQ's recent performance and forecast adjustments reflect a mix of growth opportunities and operational challenges. The company's strong position in the Life Sciences and Commodities segments, combined with its market leadership in geochemistry testing, supports its long-term potential. However, the over-raise in equity and the capex program raise questions about capital efficiency and strategic direction. The company's valuation is based on a blend of DCF and EV/EBIT, with a PT of A$18.20 reflecting its current market position and future growth prospects.